<DOC>
	<DOC>NCT01562977</DOC>
	<brief_summary>The purpose of this study is to determine efficacy of rituximab, gemcitabine, oxaliplatin and dexametasone (R-GemOx) chemotherapy schedule.</brief_summary>
	<brief_title>Study to Evaluate Efficacy and Tolerance of R-GemOx in DLBCL and MCL</brief_title>
	<detailed_description>The purpose of this study is to determine efficacy (overall response rate (ORR) and complete response) tolerance and toxicity of rituximab, gemcitabine, oxaliplatin and dexametasone (R-GemOx) chemotherapy schedule.</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Lymphoma, Mantle-Cell</mesh_term>
	<mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1. Age â‰¥ 18 years. 2. DLBCL and MCL diagnosed patients in primary resistance or relapsed not eligible for intensification chemotherapy followed by Autologous stem cell transplantation (ASCT) for age, comorbidity or previous ASCT. 3. Any IPI or ECOG, capable of understanding the nature of the trial. 4. Writtern Informed Consent. 1. Nursing pregnant or lactation period women, or fertile age adults not using effective contraceptive method. 2. CNS lymphoma patients. 3. Patients with severa renal (creatinine&gt; 2,5 UNL) or hepatic (Bilirrubin or ALT/AST&gt; 2,5 UNL) impairement not provided by the same disease 4. HIV positive patients. 5. Serious psychiatric diseases patients that could interfere with their skill to understand the study (including alcoholism or drug addiction). 6. Murine proteins or any other component of the medicines of the study hypersensitivity patients. 7. Patients who have received more than 2 therapeutic previous lines. (for previous ASCT patients, induction and conditioning for the TAPH treatment is considered a single line therapy).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>